Gilead stops re­cruit­ment in CD47 sol­id tu­mor tri­als, a week af­ter it axed blood can­cer de­vel­op­ment

Gilead has paused re­cruit­ment in­to mid-stage sol­id tu­mor tri­als of ma­grolimab just over a week af­ter it stopped de­vel­op­ment of the can­di­date in hema­to­log­i­cal can­cers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER